Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01605864 · ClinicalTrials.gov registry record · Phase 3
Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia
A Phase 3 study, sponsored by Albany Medical College.
- Completed
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT01605864 is a Phase 3 study that has completed, run by Albany Medical College. The registered enrollment target is 12 participants.
The verdict
NCT01605864, a Phase 3 study, has completed, sponsored by Albany Medical College.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
Community-acquired bacterial pneumonia, which is often called CAP, is a bacterial infection in the lungs and is treated with antibiotics. Sometimes people need to be in the hospital to be treated for CAP. Usually, hospitalized persons with CAP are given two antibiotics together. These antibiotics usually include a cephalosporin and a macrolide. The most commonly used cephalosporin at Albany Medical Center Hospital is ceftriaxone. The most commonly used macrolides at Albany Medical Center Hospital are azithromycin and doxycycline. This research is being done to find out how well a new cephalosporin antibiotic, called ceftaroline, works in combination with a macrolide for the treatment of CAP. Ceftaroline is similar to ceftriaxone. Ceftaroline was recently approved by the FDA to treat pneumonia in hospitalized patients based on two research studies. In one study, ceftaroline was better than ceftriaxone. In the second study, ceftaroline was just as good as ceftriaxone. Ceftaroline was very well tolerated in both clinical studies and it was found to be as safe as ceftriaxone.
Interventions
- DRUG Efficacy of ceftaroline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01605864
The ClinicalTrials.gov registry entry for NCT01605864 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albany Medical College, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Efficacy of ceftaroline is the first listed.
NCT01605864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01605864 about?
NCT01605864 is a clinical study titled "Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia". Community-acquired bacterial pneumonia, which is often called CAP, is a bacterial infection in the lungs and is treated with antibiotics. Sometimes people need to be in the hospital to be treated for CAP. Usually, hospitalized persons with CAP are given two antibiotics together. These antibiotics us...
What is the current status of trial NCT01605864?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2012-05. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01605864?
The interventions under investigation include: Efficacy of ceftaroline (DRUG).
Who is sponsoring clinical trial NCT01605864?
This trial is sponsored by Albany Medical College, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.